Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.

Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.

Krauss DJ, Hayek S, Amin M, Ye H, Kestin LL, Zadora S, Vicini FA, Cotant M, Brabbins DS, Ghilezan MI, Gustafson GS, Martinez AA.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e119-25. doi: 10.1016/j.ijrobp.2010.12.064. Epub 2011 May 17.

PMID:
21596486
3.

Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.

Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC.

J Urol. 1998 Aug;160(2):406-10.

PMID:
9679888
4.

Chromogranin A staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy.

Krauss DJ, Amin M, Stone B, Ye H, Hayek S, Cotant M, Hafron J, Brabbins DS.

Prostate. 2014 May;74(5):520-7. doi: 10.1002/pros.22771. Epub 2013 Dec 30.

PMID:
24375481
5.

Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.

Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V.

Urol Int. 2009;82(2):147-51. doi: 10.1159/000200789. Epub 2009 Mar 19.

PMID:
19321999
6.

Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.

Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, Cappia S, Ari MM, Tampellini M, Fontana D, Gubetta L, Angeli A, Dogliotti L.

Ann Oncol. 2001;12 Suppl 2:S159-64.

PMID:
11762345
7.

Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.

May M, Siegsmund M, Hammermann F, Loy V, Gunia S.

Scand J Urol Nephrol. 2007;41(5):375-81. Epub 2007 Jul 27.

PMID:
17853019
8.

[Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].

Wu XL, Huang KT, Chen W, Chen L, Dong L, Yu ZX.

Zhonghua Yi Xue Za Zhi. 2009 Feb 24;89(7):472-5. Chinese.

PMID:
19567097
9.

Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.

Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK.

Prostate. 2015 May;75(6):616-27. doi: 10.1002/pros.22945. Epub 2015 Jan 5.

PMID:
25560638
10.

Neuroendocrine differentiation in prostate cancer.

Cerović SJ, Brajusković GR, Vukotić Maletić VD, Mićić SR.

Vojnosanit Pregl. 2004 Sep-Oct;61(5):513-8.

PMID:
15551804
11.
12.

The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.

Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L.

Prostate. 2010 May 15;70(7):718-26. doi: 10.1002/pros.21104.

PMID:
20087896
13.

Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.

Mucci NR, Akdas G, Manely S, Rubin MA.

Hum Pathol. 2000 Apr;31(4):406-14. Erratum in: Hum Pathol 2000 Jun;31(6):778.

PMID:
10821485
14.

Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.

Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N.

Eur Urol. 2004 May;45(5):586-92; discussion 592.

PMID:
15082200
15.

The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer.

Grimaldi F, Valotto C, Barbina G, Visentini D, Trianni A, Cerruto MA, Zattoni F.

Int J Biol Markers. 2006 Oct-Dec;21(4):229-34.

PMID:
17177161
16.

Prostate cancer and neuroendocrine differentiation.

Tan MO, Karaoğlan U, Celik B, Ataoğlu O, Biri H, Bozkirli I.

Int Urol Nephrol. 1999;31(1):75-82.

PMID:
10408306
17.
18.

Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M.

World J Urol. 2008 Jun;26(3):243-50. doi: 10.1007/s00345-008-0257-0. Epub 2008 Apr 5.

PMID:
18392627
19.

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L.

Endocr Relat Cancer. 2005 Mar;12(1):109-17.

20.

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.

Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW.

Urology. 2005 Aug;66(2):386-91.

PMID:
16098367

Supplemental Content

Support Center